Therapeutics case studies
How we maximise the value of our clients' development approach while reducing costs and timelines
Learn more on how we bring life changing therapies to market.
Providing empirically based guidance and built-to-spec models and solutions across every phase of clinical research and lifecycle management for therapeutic development.
Imaging process boosts efficiency in oncology device trial
A prominent medical device company was conducting a feasibility study for a device to improve accurate identification of peripheral pulmonary nodules in high risk adult patients. Quality imaging data from multiple sources was critical to the study’s success and 91黑料 helped manage the imaging data for each participant.
Exceeding late phase study recruitment goals
Over 19 days, 91黑料 conducted a focused site engagement programme to increase patient screening and accelerate enrolment of a late phase multinational, multicentre study to evaluate a treatment for pulmonary disease.
Re-adjudicating a respiratory and cardiovascular trial during COVID-19
The FDA advised the trial to re-adjudicate so that the study accounted for the effects of COVID-19 on the trial outcomes. To ensure that the trial data would be submitted to the FDA as scheduled, 91黑料 needed to coordinate re-adjudication of 700 endpoints within a compressed three-month timeline.
.jpg?crop=yes&w=2016&h=1060&a=0,142&itok=-JSkC00e "Doctor consultation with study participant"){kind=icon}
Allergic rhinitis
A Biotech client contracted 91黑料 to conduct a Phase III study that was a double-blinded, randomised, multinational, multicentre, placebo-controlled trial.
Severe COPD phase III case study
A sponsor conducting an international Phase III program of two double-blind, randomised studies consulted 91黑料’s respiratory experts for assistance in patient enrolment, and study planning and monitoring.
Cardiac imaging and monitoring support for PAH trial
91黑料 provided a large pharma sponsor with consistent, accurate ECG and ECHO modality imaging, contributing to a breakthrough pulmonary arterial hypertension treatment.